Drugs News and Research

RSS

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Apricus Biosciences, Inc., announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ.

30 Nov 2010

To reduce spread of HIV/AIDS, IFRC calls for more focus on IDU programs

Ahead of World AIDS Day, the International Federation of the Red Cross on Friday released a report (.pdf) calling for governments around the world to do more to help stop the spread of HIV/AIDS among populations of injecting drug users (IDUs), the Associated Press reports (Heilprin, 11/25).

30 Nov 2010

Support elusive for debt panel as Wednesday deadline nears

The chairmen of a bipartisan panel appointed by President Barack Obama are altering an early draft of recommendations to reduce the nation's debt, in hopes of attracting broader support, The Wall Street Journal reports. Democrat Erskine Bowles and Republican (former) Sen. Alan Simpson "need 14 of the 18 members of the National Commission on Fiscal Responsibility and Reform to support their proposal in order to issue a formal recommendation, which could then be voted on by Congress before the end of the year.

30 Nov 2010

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. This acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data for a purchase price of approximately $15.4 million, primarily in cash and notes.

29 Nov 2010

Common, overprescribed drugs lead to election dopiness and immaturity

As Bill Maher, New York Magazine, the Washington Post and countless cable news and Internet sources have pointed out, the 2010 midterm campaigns and elections seem to have brought to light an American electorate capable of shocking illogic, ignorance and even violence.

29 Nov 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

New 'canSAR' cancer drug discovery database launched

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.

29 Nov 2010

BioTime, CIRM enter agreement for GMP-grade hES cell lines

BioTime, Inc. today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation.

29 Nov 2010

Study finds association between DGKK gene and hypospadias

Hypospadias is a common congenital malformation of the male external genitalia, affecting 1 in 375 boys. In hypospadias patients, the urethral opening is not located at the tip of the penis, but somewhere halfway, at the base of the penis, or even in the scrotum.

29 Nov 2010

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California).

29 Nov 2010

New irreversible covalent approach to inhibit viral protease

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

28 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

CQDM and Alsace BioValley enter long term research collaboration

Alsace BioValley, a French competitive health cluster dedicated to therapeutic innovation and CQDM (Québec Consortium for Drug Discovery) sign in Paris today an agreement on a bilateral partnership for the benefit of Alsatian and Quebec research centers and industries in the life sciences and health sector.

26 Nov 2010

NIH awards $6.7M to establish Membrane Protein Structural Biology Consortium

Dr. Michael G. Malkowski, Hauptman-Woodward senior research scientist, has received a $6.7 million grant from the National Institutes of Health in support of his work to establish the Membrane Protein Structural Biology Consortium (mpsbc.org) as one of nine centers in the United States responsible for determining membrane protein structures within a larger NIH biology-based initiative.

26 Nov 2010

Researchers synthesize iron compounds that inhibit growth of Mycobacterium tuberculosis

A team of researchers from Spain and Latin America have synthesized two iron compounds that inhibit the in vitro growth of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Due their low level of toxicity in mammel cells, the compounds could be used in the future as therapeutic agents and hospital disinfectants.

26 Nov 2010

Léger Marketing survey shows substance abuse problems are major concern for Quebecers

More than one in eight Quebecers think drug and alcohol dependency problems are public health issues of concern. In the Léger Marketing survey "Quebecers and Substance Abuse," released today as part of Drug Awareness Week, half of respondents say they are affected by substance abuse problems among those around them.

26 Nov 2010

Personalized oncology requires new paradigm for drug development, experts say

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice this week.

25 Nov 2010

Further studies needed over use of Proton-Pump Inhibitors in early pregnancy

Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed.

25 Nov 2010